Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

2 Apr 2009 07:00

RNS Number : 9727P
ViaLogy PLC
02 April 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

VIALOGY TO RAISE UP TO £1.5 MILLION

LONDONApril 2, 2009 - ViaLogy PLC (LSE: VIY).  The Company today announces it is to offer investors who participated in ViaLogy's 2007 and 2008 funding rounds the opportunity to exercise their warrants at a reduced price.  It is proposed that the 27,500,000 warrants issued in October 2007 ("2009 Warrants") exercisable at 10 pence per Ordinary Share will be exercisable at 2.5 pence until noon on Thursday, 30 April 2009 (the "End Date") It is further proposed that the 45,000,000 warrants issued in October 2008 ("2010 Warrants") exercisable at 5 pence per Ordinary Share will be exercisable at 2 pence until the End Date In addition, for the 1,193,654 warrants held by George Rehm and Michael Kelly, both Directors, (exercisable at 4 pence per share) and a total of 2,500,000 warrants held by Dr Richard Dixey and Mark Tompkins (exercisable at 6 pence per share) will be reduced to 2 pence per share during the same period.

Full exercise of all outstanding 2009 Warrants and 2010 Warrants prior to the End Date, at the reduced subscription prices, would raise £1,587,500 (before expenses) for the Company. After the End Date, the original subscription prices relating to all such warrants will apply.

In accordance with the terms of their constitution, the proposed variation of the subscription prices applying to the 2009 Warrants and 2010 Warrants must be approved by, and is conditional upon the passing of, extraordinary resolutions to be proposed at meetings of the holders of such warrants. Accordingly, the Company has today convened meetings of the holders of the 2009 Warrants and the 2010 Warrants to be held on Monday, 20 April 2009.

The Company has also today entered into agreements with certain institutions and individuals ("Subscribers") who have undertaken to subscribe for such number of new Ordinary Shares ("Subscriber Shares") as has an aggregate subscription price of £1,587,500, less the aggregate amount of the proceeds of the exercise of warrants by warrant holders (the "Subscription").  The aggregate number of Ordinary Shares to be subscribed by such persons shall not, however, exceed 50,377,300 (representing approximately 10 per cent. of the Company's current issued share capital), which is the maximum number of Ordinary Shares the Directors are authorised to issue for cash, pursuant to resolutions passed at the Annual General Meeting of the Company held on 29 October 2008, other than pro rata to existing shareholders. The subscription price payable for the Subscriber Shares will be determined by the number of warrants which holders of the 2009 Warrants and 2010 Warrants elect to exercise, but shall be not less than 2 pence for the first 45 million Subscriber Shares and 2.5 pence for the remaining Subscriber Shares.

In consideration of the Subscribers agreeing to subscribe for the Subscriber Shares, and so guarantee that the amount of funds to be received by ViaLogy pursuant to the proposed fundraising, (before expenses) is not less than £1,034,432.50, the Company has agreed to pay to such Subscribers an aggregate fee of £79,375 being 5% of £1,587,500, which is the maximum amount to be raised by the Company, assuming full exercise of the 2009 Warrants and the 2010 Warrants. 

Application will be made for the Ordinary Shares issued upon the valid exercise of outstanding warrants and the Subscriber Shares to be admitted to trading on AIM.

"The board decided to re-price the warrants in conjunction with the Subscription for two main reasons," said ViaLogy chairman Terry Bond. "Firstly, shareholder dilution is minimised because the warrants are already accounted for in the Company's fully diluted financial position.  Secondly, ViaLogy needs additional funding for future on-going expenditure, including the opportunity to increase our financial participation in the successful well our QuantumRD technology has identified on the Galba Oil Prospect in south central Texas.  Atascosa Exploration LLC, who commissioned us to analyse the seismic data and advise on drilling locations, were so pleased with the results that they offered us very attractive terms to double ViaLogy's working interest in the first well production to 10%. The re-pricing of the warrants seemed a very elegant solution to our funding requirements whilst minimising any dilution effect."

Ends

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

Nominated Advisor (Seymour Pierce)   Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 7628 5582 

About ViaLogy

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications.  ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential.  ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter.  This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications.  For more information, visit our website at www.ViaLogy.com. 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEDGGDSBUGGGCB
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.